Unknown

Dataset Information

0

Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.


ABSTRACT: Glioblastoma (GBM) is a highly aggressive form of brain cancer with a poor prognosis and limited treatment options. The ALK and c-MET inhibitor Crizotinib has demonstrated preclinical therapeutic potential for newly diagnosed GBM, although its efficacy is limited by poor penetration of the blood brain barrier. Here, we identify Crizotinib as a novel inhibitor of nuclear factor-κB (NF-κB)-inducing kinase, which is a key regulator of GBM growth and proliferation. We further show that the conjugation of Crizotinib to a heptamethine cyanine dye, or a near-infrared dye (IR-Crizotinib), attenuated glioma cell proliferation and survival in vitro to a greater extent than unconjugated Crizotinib. Moreover, we observed increased IR-Crizotinib localization to orthotopic mouse xenograft GBM tumors, which resulted in impaired tumor growth in vivo. Overall, IR-Crizotinib exhibited improved intracranial chemotherapeutic delivery and tumor localization with concurrent inhibition of NIK and noncanonical NF-κB signaling, thereby reducing glioma growth in vitro, as well as in vivo, and increasing survival in a preclinical rodent model.

SUBMITTER: Pflug KM 

PROVIDER: S-EPMC10698717 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.

Pflug Kathryn M KM   Lee Dong W DW   Tripathi Ashutosh A   Bankaitis Vytas A VA   Burgess Kevin K   Sitcheran Raquel R  

Molecular pharmaceutics 20231108 12


Glioblastoma (GBM) is a highly aggressive form of brain cancer with a poor prognosis and limited treatment options. The ALK and c-MET inhibitor Crizotinib has demonstrated preclinical therapeutic potential for newly diagnosed GBM, although its efficacy is limited by poor penetration of the blood brain barrier. Here, we identify Crizotinib as a novel inhibitor of nuclear factor-κB (NF-κB)-inducing kinase, which is a key regulator of GBM growth and proliferation. We further show that the conjugati  ...[more]

Similar Datasets

| S-EPMC5815365 | biostudies-literature
| S-EPMC9138991 | biostudies-literature
| S-EPMC7171155 | biostudies-literature
| S-EPMC5030170 | biostudies-literature
| S-EPMC2871283 | biostudies-literature
| S-EPMC11306741 | biostudies-literature
| S-EPMC8765003 | biostudies-literature
| S-EPMC1161108 | biostudies-other
| S-EPMC4371738 | biostudies-literature
| S-EPMC9960244 | biostudies-literature